Healthcare Industry News: SENTRIS-100
News Release - May 22, 2007
GlucoLight Corporation Announces Successful Completion of First ICU Clinical Study
BETHLEHEM, Pa.--(HSMN NewsFeed)--GlucoLight Corporation, a development-stage company focused on blood glucose monitoring in the acute care environment, today announced the successful conclusion of the company's first clinical study to evaluate their continuous non-invasive glucose monitor in the Intensive Care Unit (ICU) environment.The study, staged over 20 weeks, was performed at the Penn State Hershey Medical Center, in Hershey, PA and the Providence Heart & Vascular Institute at Providence St. Vincent Medical Center in Portland, OR. Dr Sanjay Mehta served as the Principal Investigator of the Penn State study and Dr Tony Furnary served as the Principal Investigator of the Providence/Portland based study.
The principal objective of this first ICU study was to test the form and function of GlucoLight's SENTRIS-100(TM), a continuous, non-invasive blood glucose monitoring device for the acute care environment. This clinical study was the monitor's first in the challenging clinical environment of the ICU.
Over the course of the study, 30 patients that had undergone cardiac surgery with cardiopulmonary bypass were enrolled at the participating centers. The study provided over 1,000 hours of data, collected for analysis and interpretation by GlucoLight.
"We're pleased with the initial results of our first ICU clinical study as we look to evaluate the information it yielded," said Ray Krauss, Chief Executive Officer of GlucoLight Corporation. "Our primary objective over the course of the study was to test the function of the monitor in the 'real world' environment of the ICU, the target environment for the SENTRIS-100 monitor. The clear conclusion so far is that our monitor fits into the ICU workflow, and ICU nurses found bedside operation to be straightforward and simple to execute."
GlucoLight is targeting the first introduction of the SENTRIS-100 in the ICU, where tight glycemic control has been shown to significantly improve survival, yet current monitoring provides only intermittent information.
Mr. Krauss continued, "Our initial animal studies have illustrated no distortion of the monitor's signal from changes in blood pressure or hydration, common conditions in ICU patients. The initial results of the ICU study yielded similar results in humans, and we were pleased to see prolonged periods of strong correlation between the monitor's signal and blood glucose levels in spite of the wide range of potent drugs used in the treatment of the ICU patients. Most importantly, we have the data that allows us to continue to improve the real-world accuracy of our system as we plan for another ICU study later this year. We remain confident that we will demonstrate our goal of measuring accurate glucose data in more than 95% of patients."
The GlucoLight SENTRIS-100 monitor requires regulatory clearance and is not yet commercially available.
About GlucoLight Corporation
Formed in 2003, GlucoLight is a development-stage company focused on continuous, non-invasive blood glucose monitoring in the acute care environment.
Using Optical Coherence Tomography (OCT), GlucoLight has identified specific physiological targets within the dermis that closely correlate to changes in blood glucose levels. GlucoLight's SENTRIS-100(TM) monitor samples these physiological targets every 30 seconds to track blood glucose levels to a high degree of accuracy.
Today, GlucoLight's SENTRIS-100(TM) monitor is the only continuous, non-invasive blood glucose monitor for the acute care environment that is in clinical trials.
For more information, visit www.GlucoLight.com.
Source: GlucoLight
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
